MIPI Calculator
Calculate the Mantle Cell Lymphoma International Prognostic Index (MIPI) to help estimate risk in mantle cell lymphoma.
What Is the MIPI?
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is a validated clinical tool used to stratify patients with mantle cell lymphoma (MCL) into distinct risk groups. It combines four baseline clinical variables to produce a risk score that correlates with overall survival outcomes. The MIPI is widely used in clinical practice and research to guide treatment decisions and provide prognostic information.
MIPI Components and Scoring
The MIPI score is calculated using four independent prognostic factors, each weighted according to its impact on survival:
- Age (continuous, in years)
- ECOG performance status (0–4 scale)
- Lactate dehydrogenase (LDH) ratio (serum LDH divided by the upper limit of normal)
- White blood cell count (×10⁹/L)
Each variable is assigned a point value based on predefined cutoffs. The total score determines the risk category.
MIPI Risk Categories
The total MIPI score classifies patients into three prognostic groups:
- Low risk: Score < 5.4 — median overall survival approximately 5–8 years
- Intermediate risk: Score 5.4 to < 6.2 — median overall survival approximately 3–5 years
- High risk: Score ≥ 6.2 — median overall survival approximately 1–3 years
These thresholds are derived from large cohort studies and have been validated across multiple independent patient populations.
How the MIPI Calculator Works
The calculator applies the original MIPI formula to the four input variables. It computes a continuous score using the following weighted equation:
MIPI score = [0.035 × age (years)] + [0.697 × (ECOG > 1)] + [0.530 × log₂(LDH ratio)] + [0.024 × WBC (×10⁹/L)]
The resulting value is compared against the established risk cutoffs to assign the prognostic category. The calculator handles decimal inputs and provides the score rounded to two decimal places for clinical clarity.
Interpreting Your Results
The MIPI provides a statistical estimate of prognosis based on population-level data. It does not predict individual outcomes with certainty. Consider the following when reviewing results:
- The MIPI reflects risk at the time of diagnosis and may change with disease progression or treatment response.
- Additional factors such as Ki-67 proliferation index, blastoid morphology, and TP53 mutation status may provide further prognostic information beyond the MIPI.
- The MIPI is one component of clinical assessment and should not replace comprehensive evaluation by a hematologist or oncologist.
Common Considerations When Using the MIPI
- ECOG scoring: Ensure performance status is assessed accurately. ECOG 0–1 indicates fully active or restricted in physically strenuous activity; ECOG ≥ 2 indicates significant functional limitation.
- LDH ratio: Use the most recent pre-treatment LDH value divided by your institution's upper limit of normal. Different laboratories may have different reference ranges.
- White blood cell count: Use the absolute count, not the percentage. Ensure units are in ×10⁹/L (equivalent to cells/µL divided by 1000).
- Age: Enter the patient's age in whole years at the time of diagnosis.
Limitations of the MIPI
The MIPI was developed and validated primarily in patients treated with conventional chemotherapy regimens. Its prognostic accuracy may differ in patients receiving novel therapies such as BTK inhibitors, CAR-T cell therapy, or bispecific antibodies. The index does not account for tumor biology, genetic mutations, or treatment response. For patients with relapsed or refractory disease, other prognostic models may be more appropriate.
Practical Use Cases
- Initial risk stratification at diagnosis to inform treatment intensity and clinical trial eligibility
- Patient counseling regarding expected outcomes and treatment goals
- Clinical research for cohort characterization and outcome analysis
- Treatment planning in conjunction with other clinical and laboratory findings
FAQ
What is the difference between MIPI and MIPI-c?
The MIPI-c (combined MIPI) incorporates Ki-67 proliferation index into the original MIPI score. Ki-67 is measured by immunohistochemistry and reflects tumor cell proliferation. The MIPI-c may provide additional prognostic discrimination, particularly in intermediate-risk patients. However, Ki-67 measurement is not standardized across laboratories, which can affect reproducibility.
Can the MIPI be used for all mantle cell lymphoma patients?
The MIPI was validated in newly diagnosed patients with mantle cell lymphoma. Its use in relapsed/refractory disease, transformed disease, or patients with significant comorbidities has not been formally validated. Clinical judgment should guide interpretation in these populations.
How often should the MIPI be recalculated?
The MIPI is intended for baseline risk assessment at diagnosis. It is not designed for serial monitoring during treatment. Changes in clinical status or disease progression may warrant reassessment using other prognostic tools.
Does the MIPI predict response to specific treatments?
No. The MIPI predicts overall survival risk but does not predict response to any particular therapy. Treatment decisions should be based on current clinical guidelines, patient fitness, disease characteristics, and shared decision-making.
What if my LDH is within normal range?
An LDH ratio of 1.0 or less is common and contributes a lower score to the MIPI. This is expected and does not indicate an error. The calculator handles normal LDH values appropriately.